Hostname: page-component-7b7567c8c-w7t8q Total loading time: 0 Render date: 2026-11-18T10:03:04.622Z Has data issue: false hasContentIssue false

Low-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: an effect size analysis

Published online by Cambridge University Press:  16 April 2020

C Barbui
Affiliation:
Laboratory of Epidemiology and Social Psychiatry, ‘Mario Negri’ Institute for Pharmacological Research, Via Eritrea 62, 20157Milan, Italy
B Saraceno
Affiliation:
Laboratory of Epidemiology and Social Psychiatry, ‘Mario Negri’ Institute for Pharmacological Research, Via Eritrea 62, 20157Milan, Italy
Get access

Summary

A meta-analysis of the published literature was performed in order to quantify the efficacy of low-dose neuroleptic therapy in reducing extrapyramidal side effects in schizophrenic patients. A low-dose regimen between 50–100 mg equivalents of chlorpromazine, in comparison to a standard-dose regimen between 200–500 mg reduced extrapyramidal side effects by a 0.30 (±0.12) standard deviation, which is only a limited effect.

Information

Type
Short communications
Copyright
Copyright © Elsevier, Paris 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Submit a response

Comments

No Comments have been published for this article.